Edgewise Therapeutics, Inc. research snapshot
EWTX AI stock analysis now reads Edgewise Therapeutics as a cardiovascular-focused, pre-revenue biotech that completed the sale of its muscular dystrophy business to Servier on July 13, 2026, receiving $1.55 billion in upfront cash with up to $1.1 billion in milestones. At the July 31, 2026 close, the quoted price was $38.43 and the market capitalization was about $4.13 billion, while positive but underwhelming 12-week Phase 2 CIRRUS-HCM data for lead asset EDG-7500 set up a Phase 3 trial expected in Q4 2026. The main decision point is whether the cardiovascular pipeline can convert recent catalysts into Phase 3 success, because the cash-rich balance sheet supports the business but the clinical outcomes remain binary. This is informational research and not investment advice.
Current price
$38.43
Market cap
$4.13 billion
AI score
56 / 100
Rating
Cash-rich cardiovascular pivot, binary Phase 3 risk
Trend status
Strong uptrend with post-deal pullback, above key moving averages
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Edgewise is a pre-revenue biotech now focused on muscle-targeted cardiovascular therapies. The Servier deal removed the muscular dystrophy business and left the company dependent on EDG-7500, EDG-15400, and EDG-003 for standalone value. | Medium |
| Moat | The moat is in its muscle biology expertise and cardiac sarcomere modulator platform. Competitors include Cytokinetics and Bristol Myers in HCM, but EDG-7500 uses a distinct non-contractile mechanism that is unproven until Phase 3. | Low |
| Management | Management completed a transformative Servier deal that converted sevasemten into $1.55 billion of upfront cash and refocused the company on the cardiovascular pipeline. The team has deep muscle biology experience, and execution discipline now shows in the balance sheet. | Medium |
| Financial trend | Pre-revenue with negative EPS and steady cash burn. After the Servier close, estimated cash of roughly $2.05 billion is expected to fully fund EDG-7500 development through potential approval, removing the near-term funding overhang. | Medium |
| Valuation | Traditional P/E does not apply to a pre-revenue biotech. With a $4.13 billion market cap and roughly $2.05 billion of net cash, the post-deal enterprise value of about $2.08 billion prices meaningful EDG-7500 Phase 3 and commercial success. The cash cushion supports a partial floor. | Low |
| Technical trend | Strong uptrend with the stock well above the 200-day moving average. Price pulled back from the $48.40 high after the deal closed and now sits near the 50-day average around $38. Use live moving averages, support, resistance, volume, and invalidation levels before acting. | Medium |
| Risk level | The thesis can fail if EDG-7500 Phase 3 HCM data disappoint, Phase 2 efficacy skepticism persists, competitive HCM therapies reach the market first, Servier milestones are not met, or the company issues dilutive equity. | Medium-high |
| AI confidence | Medium data confidence for qualitative mapping and balance-sheet math. Lower confidence for binary clinical outcomes and stock price prediction. | Medium data confidence |
| Investment certainty | Low certainty because the page gives a framework, not a personalized buy or sell instruction. Biotech stocks carry binary clinical risk even with a strong cash position. | Low |
EWTX AI stock forecast
The EWTX AI stock forecast uses scenario ranges around the $38.43 quote rather than a point target. The bullish case depends on EDG-7500 Phase 3 progress, positive follow-on data, and EDG-15400 momentum; the base case assumes steady pipeline execution while the market waits for Phase 3; the bearish case assumes clinical setbacks or competitive pressure despite the cash cushion.
$52.00 to $62.00
More likely if EDG-7500 Phase 3 initiates cleanly in Q4 2026 with a design investors trust, follow-on data confirm the Phase 2 signal, EDG-15400 Phase 2 shows promise in HFpEF, and Servier milestone payments arrive without dilution.
$36.00 to $48.00
More likely if pipeline progress is steady but incremental, the stock holds above its moving averages near analyst consensus while the market waits for Phase 3 data, EDG-15400 readouts, and the August 2026 earnings report.
$24.00 to $32.00
More likely if these risk paths appear: EDG-7500 Phase 3 data disappoint or are delayed, investor skepticism from the Phase 2 reaction persists, competitive HCM programs advance faster, or the company needs dilutive financing despite its cash.
EWTX AI technical analysis
EWTX AI technical analysis starts from the $38.43 quote and the observed 52-week range of $12.30 to $48.40. Because this static page does not fetch request-time chart data, moving averages and live momentum should be confirmed in a charting tool before use.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $38.43 | Close as of July 31, 2026, used for this page with the August 2026 data cutoff. |
| Near support | $36.00 to $38.00 | Estimated from the post-deal consolidation range and the July 17 low near $37. Treat as a planning zone, not a guaranteed floor. |
| Near resistance | $41.00 to $46.00 | The $48.40 level is the 52-week high reached just before the Servier deal closed. A close above the low-$40s zone with volume would signal a new uptrend leg. |
| 50-day moving average | $38.26 | Price sits just above the 50-day average. A decisive close below it would mark a short-term trend shift. |
| 200-day moving average | $29.72 | The stock trades well above the 200-day average, confirming the longer-term uptrend from earlier in the year. |
| Momentum | Positive longer-term trend with short-term pullback | The Servier deal and HCM data drove a strong run into the $48.40 high. Profit-taking after the deal close is normal. |
| Volume | Elevated volume on catalyst days | Volume spiked on the Servier announcement, the CIRRUS-HCM readout, and the deal close. Lower volume during the recent consolidation may indicate indecision. |
| Volatility | Very high monitoring priority | Biotech stocks can swing 10-20% on clinical data or deal news. Use position sizing that can tolerate wide daily movement. |
| Invalidation | Close below $36.00 | A decisive close below the support zone on elevated volume would weaken the bullish setup significantly and open the path toward the $33 to $35 area. |
EWTX AI trading strategy
The EWTX AI trading strategy is a rules-based research framework. It is not personalized advice and should be paired with position sizing, stop levels, and fresh pipeline, deal, and earnings updates.
Wait for EWTX to hold above near support and push through the $41 to $42 resistance zone with volume that confirms renewed buyer interest after the post-deal pullback.
A close below the $36.00 support zone or a failed breakout should invalidate the setup. Biotech binary events can trigger gap moves.
If EWTX falls toward the $36 to $38 support band on no negative news, compare the pullback with the Phase 3 timeline, EDG-15400 plans, earnings on August 6, 2026, and overall biotech sentiment.
Do not average down without a predefined maximum loss and a fresh review of the clinical timeline and Servier milestone risks.
Watch for the Q2 2026 earnings report, EDG-7500 Phase 3 trial initiation, EDG-15400 Phase 2 updates, or Servier milestone announcements. Position size should reflect binary outcome risk, and limit orders should be used instead of market orders around catalyst events.
Consider reducing position size before binary events. Gaps against the position are possible and may exceed standard stop levels.
Investment research summary
Edgewise Therapeutics is a cardiovascular-focused, clinical-stage biopharmaceutical company developing novel oral small-molecule therapies for muscle-related heart conditions. After selling sevasemten to Servier, the core platform targets cardiac sarcomere proteins through EDG-7500 for hypertrophic cardiomyopathy, EDG-15400 for HFpEF, and EDG-003.
The moat is in its proprietary muscle biology platform and cardiac sarcomere modulator mechanism. EDG-7500 targets a different mechanism than existing HCM therapies, but the moat is unproven until Phase 3 data and commercial validation arrive.
The thesis can fail if EDG-7500 Phase 3 HCM data disappoint, investor skepticism from the June 2026 Phase 2 reaction persists, competitive HCM therapies such as Cytokinetics aficamten or BMS mavacamten dominate the market, or the company raises dilutive equity despite its large cash position.
Management completed the transformative Servier transaction on July 13, 2026, converting the muscular dystrophy program into $1.55 billion of upfront cash and roughly $2.05 billion of estimated total cash. The key question is whether the team can advance EDG-7500 through Phase 3 and build the cardiovascular pipeline with that capital.
HCM is a validated market with approved therapies and a large addressable patient population, while HFpEF is a large unmet need. The Servier deal shows that pharmaceutical companies value muscle disease assets, which supports the cardiovascular-focused repositioning.
Traditional P/E does not apply. With roughly $2.05 billion of post-deal cash, about $19.05 per share, against a $4.13 billion market cap, the enterprise value of about $2.08 billion prices EDG-7500 at significant probability of success. The cash cushion provides a partial floor, but margin of safety is thin if clinical or regulatory setbacks occur.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| EWTX price | $38.43 close on July 31, 2026 | StockAnalysis.com real-time quote data | August 2, 2026 |
| Market capitalization | $4.13 billion, verified as $38.43 x 107.59 million shares with 0.11% deviation | financial_rigor.py market cap verification against StockAnalysis.com | August 2, 2026 |
| Shares outstanding | 107.59 million, up 12.32% year over year | StockAnalysis.com statistics page | August 2, 2026 |
| Post-deal cash position | $499.56 million at March 31, 2026 plus $1.55 billion Servier upfront = about $2.05 billion estimated, or about $19.05 per share | StockAnalysis.com balance sheet cross-checked with Edgewise press release of July 13, 2026 | August 2, 2026 |
| 52-week range | $12.30 to $48.40 | StockAnalysis.com statistics page | August 2, 2026 |
| Analyst price target | $49.92 average consensus with a range of roughly $32.00 to $66.00 | StockAnalysis.com analyst forecast and TheFly price target updates | August 2, 2026 |
| TTM net income and EPS | Net income of -$176.01 million and EPS of -$1.66 | StockAnalysis.com financials page | August 2, 2026 |
This EWTX AI stock analysis page is an informational tool only. It is not investment advice, a recommendation, or a promise of future returns. Forecast scenarios are based on available data as of August 2, 2026, may be incomplete, and can be wrong if new clinical data, deal terms, market prices, company events, or macro conditions change. Biotech stocks carry binary clinical and regulatory risks even when the balance sheet is strong.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
